Research programme: MCP1 splice variant - CompugenAlternative Names: CGEN-54; Research programme: monocyte chemoattractant protein 1 splice variant - Compugen
Latest Information Update: 03 Sep 2009
At a glance
- Originator Compugen
- Mechanism of Action CCR2 receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Suspended Inflammation
Most Recent Events
- 01 Nov 2006 Preclinical trials in Inflammation in Israel (unspecified route)